[
    [
        {
            "time": "2019-01-01",
            "original_text": "Pharma Stocks That Could Cure Ailing Portfolios in 2019",
            "features": {
                "keywords": [
                    "pharma",
                    "cure",
                    "portfolios"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pharma Stocks That Could Cure Ailing Portfolios in 2019",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "Why Neurocrine Biosciences Is Tanking",
            "features": {
                "keywords": [
                    "neurocrine",
                    "biosciences",
                    "tanking"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Why Neurocrine Biosciences Is Tanking",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "Notable ETF Outflow Detected - XLV, ABBV, ABT, CVS",
            "features": {
                "keywords": [
                    "etf",
                    "outflow",
                    "xlv",
                    "abbv",
                    "abt",
                    "cvs"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Notable ETF Outflow Detected - XLV, ABBV, ABT, CVS",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recenity": 7
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019",
            "features": {
                "keywords": [
                    "biotech",
                    "bounce back"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "Mavyret Is a Leading Drug in AbbVie’s HCV Franchise",
            "features": {
                "keywords": [
                    "mavyret",
                    "leading drug",
                    "abbvie",
                    "hcv"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Mavyret Is a Leading Drug in AbbVie’s HCV Franchise",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "AbbVie - High Yield at a Low Valuation",
            "features": {
                "keywords": [
                    "abbvie",
                    "high yield",
                    "low valuation"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie - High Yield at a Low Valuation",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]